Programme


Cardiff Programme – Tuesday 9th October 2018


16:30 Arrivals & badge collection
17:30 – 17:35 Welcome, introduction and overview of agenda
Professor Christopher Fegan
Consultant Haematologist, University Hospital of Wales
17:35 – 18:00 Recent genetic insights into lymphoma
Professor Jude Fitzgibbon
Professor of Personalised Cancer Medicine, Barts Cancer institute, London
18:00 – 18:25 Clinical trials in lymphoma
Professor Andy Pettitt
Professor of Haematology & Honorary Consultant Haematologist, The Royal Liverpool University Hospital
18:25 – 18:50 Targeting mTOR kinase-mediated signaling pathways in CLL
Dr Alison Michie
Reader, Paul O’Gorman Leukaemia Research Centre, The University of Glasgow
18:50 – 19:15 Advancing strategies to treat relapsed or refractory follicular lymphoma
Dr Graham Collins
Consultant Haematologist Oxford University Hospitals NHS Foundation Trust
19:15 – 19:40 Buffet Dinner
19:40 – 20:05 The tumour micro-environment
Professor Klaus Okkenhaug
Professor of Immunology, Head of the Division of Immunology, The University of Cambridge
20:05 – 20:30 How much have targeted agents advanced the management of relapsed/refractory CLL?
Dr Renata Walewska
Haematologist, Royal Bournemouth Hospital
20:30 Closing Remarks
Professor Christopher Fegan
Consultant Haematologist, University Hospital of Wales

 

ONC/UK/19-03/PMAR/1117f(1)
Date of preparation: June 2019

This activity is intended for medical Haematology/Oncology healthcare professionals, scientists and academics involved in the management of, and research into CAR T-cell therapy in patients with high-grade lymphoid malignancies, specifically relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), as well as those with interest in the wider treatment landscape of haematological malignancies. Data on licensed CAR-T products will be presented.